Drug intelligence / Profile preview

Ifosfamide + Carboplatin + Paclitaxel + Fluorouracil

Development stage: Unknown
Lead developer: NuGen Medical Devices
Modality: Small Molecules
Administration: Intravenous

Overview

This combination involves four chemotherapeutic agents: ifosfamide, carboplatin, paclitaxel, and fluorouracil. **Ifosfamide** is an alkylating agent that works by forming DNA cross-links, which inhibits DNA replication and transcription, leading to cell death. **Carboplatin** is a platinum-based drug that interferes with DNA replication, causing cell death. **Paclitaxel** is a taxane that stabilizes microtubules, preventing cell division. **Fluorouracil (5-FU)** is an antimetabolite that interferes with DNA synthesis. This combination is used in cancer treatment, potentially in advanced or recurrent cases.

Targets

TS (Thymidylate synthase)DNAMicrotubule

Beyond the preview

Go deeper on Ifosfamide + Carboplatin + Paclitaxel + Fluorouracil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ifosfamide + Carboplatin + Paclitaxel + Fluorouracil.

Explore the full profile